Search Results
The Compleat Oncologist
Rodger J. Winn
Antiemetic Guidelines: Not Just for the HEC of It
Kelsey A. Klute
Nausea and vomiting are among the most feared complications of chemotherapy. 1 Clinicians often reassure people starting chemotherapy that, “It’s not like on TV. We have better medicines to manage nausea and vomiting now. We don’t see many patients
Antiemesis
David S. Ettinger, Debra K. Armstrong, Sally Barbour, Michael J. Berger, Philip J. Bierman, Bob Bradbury, Georgianna Ellis, Steve Kirkegaard, Dwight D. Kloth, Mark G. Kris, Dean Lim, Laura Boehnke Michaud, Lida Nabati, Kim Noonan, Hope S. Rugo, Darby Siler, Steven M. Sorscher, Sundae Stelts, Lisa Stucky-Marshall, Barbara Todaro, and Susan G. Urba
Overview Chemotherapy-induced (or radiotherapy-induced) vomiting (emesis) and nausea can significantly affect a patient’s quality of life, leading to poor compliance with further chemotherapy or radiation therapy treatment. Nausea and vomiting
Erratum
;21[5]: 473–479.e4 ; doi: 10.6004/jnccn.2022.7101 ), Figure 1 was printed incorrectly. The starting points of the lines for G3 fatigue; G2 nausea; and G1 anemia should have been positioned farther to the right. The figure is printed correctly below
CLO20-057: A Meta-Analysis on Gastrointestinal (GI) and Hepatic Toxicities Associated With Upfront Use of Immune Checkpoint Inhibitor and Anti-Angiogenic Tyrosine Kinase Inhibitor Combinations for Advanced Renal Cell Carcinoma
Miguel Angel Quirch, Nusrat Jahan, Meda Srikala, Fred Hardwicke, and Lukman Tijani
1.26 (95% CI: 1.15-1.38, P<0.00001, I2 =0%); dyspepsia:0.40 (95% CI: 0.30-0.53, P<0.00001, I2 = 0%); nausea: 0.87(95% CI: 0.76-1.00, P=0.05, I2 =0%); vomiting: 0.88(95% CI: 0.72-1.07, P= 0.20, I2 =0%), abdominal pain: 1.50 (95% CI:1.13-1.99, P=0
CLO24-084: Myeloid Sarcoma in a Patient With Marfan Syndrome
Nitya Batra, Atulya Aman Khosla, Shyam Poudel, and Daniel Ezekwudo
manifestation of MS presenting as small bowel obstruction in a patient with Marfan Syndrome. Case: A 37-year-old male with a medical history significant for Marfan syndrome, thoracoabdominal aortic aneurysm presented to the emergency department with nausea
CLO22-056: Phase I Trial of Concurrent Nab-paclitaxel and Cisplatin With Radiotherapy for Locally Advanced Cervical Cancer
Ping Jiang, Ang Qu, Weijuan Jiang, Xiuwen Deng, and Junjie Wang
twice a week. Dose escalation followed a 3 + 3 design. The DLT was defined as grade 3 or 4 nonhematologic toxicity, excluding nausea, vomiting and alopecia, decreased appetite and fatigue, or grade 4 hematologic toxicity. Results : This study was
CLO22-045: Gastrointestinal Safety Profile of Sonic Hedgehog Inhibitors in Basal Cell Carcinoma (BCC): A Systematic Review and Meta-analysis
Muhammad Zain Farooq, Mishal Shan Siddiqui, Syed Ali Farhan, Mahima Khatri, Syed Hamza Bin Waqar, Saad Khalid, and Ankit Mangla
nausea/vomiting, 19% (n=331) reported diarrhea, 10.3% (n=177) had abdominal pain and 9.4% (n=164) had constipation. Liver enzymes were deranged in 14.9% of subjects. Less frequent toxicities were dyspepsia 1%, gastric ulcer/gastritis 0.7%, GI hemorrhage 0
HSR20-076: Provider Versus Patient Reported Outcomes (PROs) in Colorectal Cancer (CRC) Patients (pts) Undergoing Systemic Therapy (Ctx): A Real World Experience
Sonali Agrawal, Caitlin R. Meeker, Sandeep Aggarwal, Elizabeth A. Handorf, Sunil Adige, Efrat Dotan, Crystal S. Denlinger, William H. Ward, Jeffrey M. Farma, and Namrata Vijayvergia
or require a dose modification (mouth sores, diarrhea, nausea, vomiting, rash, hand-foot syndrome, and neuropathy). Exact McNemar’s test was used to analyze agreement in reporting between patient and provider for each tox. Results: Of 40 pts
NCCN News
! 2013 ; 18 : 3 . New NCCN Patient Education Materials Help Patients Combat Nausea and Vomiting; New Patient App Now Available To inform patients about their treatment options and help them combat nausea and vomiting during
